| Biomarker ID | 1752 |
| PMID | 30758971 |
| Year | 2019 |
| Biomarker | Gleason score+age,+pre-operative PSA +pathological stage+Tyrosine+Methylguanine+Isoleucine+Hypoxanthine+Maleic Acid +Xanthurenic acid 3+ LPC(18:0e)+LPC(22:3)+SM(d16:1/14:0)+DG(16:0/24:6)+SM(d16:1/24:3)+TG(15:0/16:1/18:2)+TG(16:0/18:1/18:2)+TG(18:1/18:1/18:1)+TG(18:0/18:1/22:5)+LPI(16:0) +Cer(d18:1/24:1) +Leucine+Glucose+Inosine |
| Biomarker Basis | Mass/Charge Ratio |
| Biomolecule | Lipid |
| Source | Serum |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | 40 patients with biochemical Recurrence and 40 with remission (no recurrence) were selected for the study |
| Senstivity | 90.6% |
| Specificity | 94.4% |
| AUC | NA |
| Accuracy | 91.1% |
| Level Of Significance | NA |
| Method Used | mass spectrometry (MS) +liquid chromatography (LC) separations, nuclear magnetic resonance (NMR) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |